AMRN

Amarin Corporation plc (NASDAQ:AMRN) is an Irish pharmaceutical company founded in 1989 that focuses on developing and commercializing cardiovascular therapeutics. Originally incorporated as Ethical Holdings plc, the company changed its name to Amarin Corporation plc in 1999 and went public in 1993. Headquartered in Dublin, Ireland, Amarin has built its business around a single primary product: VASCEPA, a prescription omega-3 fatty acid medication used to reduce cardiovascular risk and treat severe hypertriglyceridemia. The company has evolved from a development-stage biotechnology firm into a commercial pharmaceutical company with operations spanning the United States, Europe, and emerging global markets.